GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zenotech Laboratories Ltd (BOM:532039) » Definitions » Cash-to-Debt

Zenotech Laboratories (BOM:532039) Cash-to-Debt : N/A (As of Jun. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Zenotech Laboratories Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zenotech Laboratories's cash to debt ratio for the quarter that ended in Jun. 2024 was N/A.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Zenotech Laboratories's Cash-to-Debt or its related term are showing as below:

BOM:532039' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01   Med: 0.34   Max: No Debt
Current: No Debt

During the past 13 years, Zenotech Laboratories's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 0.34.

BOM:532039's Cash-to-Debt is ranked better than
99.81% of 1038 companies
in the Drug Manufacturers industry
Industry Median: 0.885 vs BOM:532039: No Debt

Zenotech Laboratories Cash-to-Debt Historical Data

The historical data trend for Zenotech Laboratories's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zenotech Laboratories Cash-to-Debt Chart

Zenotech Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.12 0.40 No Debt No Debt

Zenotech Laboratories Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A No Debt N/A No Debt N/A

Competitive Comparison of Zenotech Laboratories's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Zenotech Laboratories's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenotech Laboratories's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zenotech Laboratories's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zenotech Laboratories's Cash-to-Debt falls into.



Zenotech Laboratories Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zenotech Laboratories's Cash to Debt Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Zenotech Laboratories had no debt (1).

Zenotech Laboratories's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zenotech Laboratories  (BOM:532039) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


Zenotech Laboratories Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zenotech Laboratories's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenotech Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Survey No. 250-252, Turkapally Village, Shamirpet Mandal, RR District, Hyderabad, TG, IND, 500 078
Zenotech Laboratories Ltd is an India-based pharmaceutical company. It is a pharmaceutical specialty generic injectables company engaged in the area of manufacturing biotechnology products. The Company's injectables product portfolio primarily serves niche therapy areas like oncology and anesthesiology. It also manufactures products such as granulocyte-colony stimulating factor (GCSF) and Granulocyte-macrophage colony-stimulating factor (GMCSF). The company earns a vast majority of the revenue from the sale of its contract research and manufacturing services.

Zenotech Laboratories Headlines

No Headlines